X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (26) 26
index medicus (23) 23
humans (21) 21
prognosis (21) 21
bendamustine (17) 17
internal medicine (17) 17
relapse refractory (17) 17
t cells (17) 17
female (16) 16
flow cytometry (16) 16
cd117 (15) 15
co-culture (15) 15
diseases of the blood and blood-forming organs (15) 15
international prognostic scoring system (15) 15
male (15) 15
mesenchymal stem cells (15) 15
non-hodgkin lymphoma (15) 15
reverse transcription-polymerase chain reaction (15) 15
telomere-binding proteins (15) 15
world health organization prognostic scoring system (15) 15
middle aged (14) 14
miscarriages (14) 14
thrombophilia (14) 14
adult (13) 13
blood processing (13) 13
donors (13) 13
transfusion strategy (13) 13
factor v deficiency (12) 12
phenotype (12) 12
rare bleeding disorders (12) 12
aged (11) 11
bacteremia (11) 11
genotype (11) 11
il-10 (11) 11
il-6 (11) 11
il-8 (11) 11
t?p (11) 11
codon (10) 10
relapse/refractory (10) 10
sickle/β (10) 10
thalassemia (10) 10
therapy (9) 9
adolescent (8) 8
bone marrow aspirate smear (8) 8
chemotherapy (8) 8
multiple myeloma (7) 7
patients (7) 7
recurrence (7) 7
splenectomy (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
letter to the editor (6) 6
lymphomas (6) 6
oncology (6) 6
relapse (6) 6
sweet’s syndrome (6) 6
aged, 80 and over (5) 5
antineoplastic agents - therapeutic use (5) 5
metastatic adenocarcinoma (5) 5
pet/ct (5) 5
reed-sternberg cells (5) 5
stem cells (5) 5
survival rate (5) 5
antidepressant (4) 4
blood platelets (4) 4
cancer (4) 4
chronic lymphocytic leukemia (4) 4
disease-free survival (4) 4
efficacy (4) 4
gardner-diamond syndrome (4) 4
laboratories (4) 4
lymphoma (4) 4
medicine, general & internal (4) 4
mortality (4) 4
mutation (4) 4
refractory (4) 4
retrospective studies (4) 4
rituximab (4) 4
survival (4) 4
transplantation (4) 4
treatment outcome (4) 4
antineoplastic agents - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
blood (3) 3
bone marrow (3) 3
brentuximab vedotin (3) 3
brief report (3) 3
child (3) 3
combined modality therapy (3) 3
disease (3) 3
health risk assessment (3) 3
hematology, oncology and palliative medicine (3) 3
images in hematology (3) 3
kit d816v (3) 3
lenalidomide (3) 3
leukemia (3) 3
lymphoma, non-hodgkin - drug therapy (3) 3
non-hodgkin-lymphoma (3) 3
non-hodgkins-lymphoma (3) 3
phase-ii (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, Issue 9, pp. 560 - 569
Multiple myeloma (MM) usually follows a clinical course leading to refractoriness and limited treatment options in advanced stages, which might need bridge... 
mCBAD | Relapse/refractory MM | Newly diagnosed MM | High-risk MM | Multiple myeloma | DARATUMUMAB | CRITERIA | POMALIDOMIDE | THERAPY | ONCOLOGY | LENALIDOMIDE | HEMATOLOGY | EXPRESSION | HYPERCVAD
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2017, Volume 176, Issue 5, pp. 750 - 758
Journal Article
Journal of Internal Medicine, ISSN 0954-6820, 03/2017, Volume 281, Issue 3, pp. 247 - 260
Journal Article
Journal Article
Journal of Medical Economics, ISSN 1369-6998, 01/2019, Volume 22, Issue 1, pp. 16 - 25
Aims: Patients with classical Hodgkin's lymphoma (cHL) who have relapsed after or are ineligible for autologous stem cell transplantation (ASCT) have limited... 
pembrolizumab | classical Hodgkin's lymphoma | relapse/refractory | cost-utility | economic evaluation | Cost-effectiveness | brentuximab vedotin | STEM-CELL-TRANSPLANTATION | PHASE-II | GEMCITABINE | SALVAGE TREATMENT | MEDICINE, GENERAL & INTERNAL | THERAPY | AUTOLOGOUS BONE-MARROW | DISEASE | HEALTH CARE SCIENCES & SERVICES | HIGH-DOSE CHEMOTHERAPY | HEALTH | BLOOD
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 5, pp. 684 - 689
Journal Article
Swiss Medical Weekly, ISSN 1424-7860, 07/2018, Volume 148, Issue 29-30, p. w14635
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 12/2014, Volume 7, Issue 6, pp. 719 - 731
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of... 
Pomalidomide | Immunomodulation | IMiDs | Multiple myeloma | Relapse refractory | SURVIVAL | immunomodulation | multiple myeloma | CC-4047 | PROLIFERATION | THALIDOMIDE | BORTEZOMIB | CEREBLON EXPRESSION | pomalidomide | relapse refractory | THERAPY | LENALIDOMIDE | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | ADVERSE EVENTS
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 3/2013, Volume 139, Issue 3, pp. 499 - 508
Journal Article
Journal Article
Journal Article